JUPITER, Fla.--(BUSINESS WIRE)--DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the ...

Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- In ...

MALVERN, Pa. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

For complicated urinary tract infection, the efficacy and safety of the investigational cefepime–taniborbactam combination, in comparison with standard treatment with meropenem, are unknown. New ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...